

Journal Information

Journal Title	JOURNAL OF CHEMOTHERAPY
Publisher	TAYLOR & FRANCIS LTD
ISSN	1120-009X
E-ISSN	1973-9478
Database	Clarivate
Domain	Health Sciences, Life Sciences, Physical Sciences

Classification History

Year	A+	A	B	C
2026		✓	✓	
2025		✓	✓	
2024		✓	✓	
2023		✓	✓	
2021/2022		✓	✓	
2020		✓	✓	
2019		✓	✓	
2018		✓		

Classification: The table above shows all journal classifications recorded for each classification year in the Green Journals database. A journal may have more than one classification in the same year.

Recent Articles

Time-dependent indirect comparison of enfortumab vedotin plus pembrolizumab and disitamab vedotin plus toripalimab in advanced urothelial carcinoma 2026-10-29 Pages 1-5 Authors: Hiroki Tanaka, Hiroshi Fukushima, Wei Chen et al. DOI: 10.1080/1120009x.2026.2751380
Integrative topological and longitudinal transcriptomic analyses identify a 14-gene interferon-stimulated module associated with acquired sunitinib resistance in clear cell renal cell carcinoma 2026-10-22 Pages 1-11 Authors: Wenhao Chu, Fuhao Wang, Liangkuan Bi et al. DOI: 10.1080/1120009x.2026.2751379
Emerging roles of long non-coding RNA CASC2 in tumor chemoresistance - a review 2026-10-4 Pages 1-16 Authors: Lingyun Zhou, Jintao He, Wenbing Huang et al. DOI: 10.1080/1120009x.2026.2739728
Hepatic arterial infusion chemotherapy plus lenvatinib with or without PD-1 inhibition for unresectable hepatocellular carcinoma: a retrospective cohort study 2026-9-30 Pages 1-16 Authors: Haidong Yu, Cunkai Ma, Cairang Yangdan et al. DOI: 10.1080/1120009x.2026.2737018

<p>Longitudinal acquisition and infection risk associated with multidrug-resistant organisms and <i>Candida</i> colonization in intensive care unit patients</p> <p>2026-9-12 Pages 1-15 Authors: Ülkü Altöparlak, Hatice Erdoğan, Mine Çelik et al. DOI: 10.1080/1120009x.2026.2732415</p>
<p>Circular RNAs: key regulators and mechanistic insights in breast cancer drug resistance</p> <p>2026-9-10 Pages 1-23 Authors: Yaxuan Zhao, Xiaoyong Lei, Xiaoyan Yang DOI: 10.1080/1120009x.2026.2729966</p>
<p>Tumor resistance to protein kinase inhibitors</p> <p>2026-9-10 Pages 1-15 Authors: Mridul Singh Sengar, Ajita Paliwal, Niranjana Kaushik et al. DOI: 10.1080/1120009x.2026.2728432</p>
<p>First-line therapy and maintenance outcomes in Chinese patients with marginal zone lymphoma: a multicenter retrospective analysis with prognostic implications for chemotherapy decision-making</p> <p>2026-9-5 Pages 1-9 Authors: Yanyan Qiu, Yimei Weng, Xinyuan Su et al. DOI: 10.1080/1120009x.2026.2727267</p>
<p>The epigenetic regulator ALKBH5 facilitates the early adaptation of hepatocellular carcinoma cells to sorafenib treatment</p> <p>2026-9-3 Pages 1-17 Authors: Meng Li, Jiayu Wang, Shuai Fang et al. DOI: 10.1080/1120009x.2026.2722741</p>
<p>Targeting glutaminase (GLS) to suppress CXCL8 secretion and sensitize esophageal squamous cell carcinoma to immunotherapy</p> <p>2026-9-1 Pages 1-17 Authors: Xiu Zhang, Jiang Chao, Zhuqing Ji et al. DOI: 10.1080/1120009x.2026.2722740</p>